|
Sign In to gain access to subscriptions and/or personal tools.
|
Multiple Sclerosis, Vol. 6, No. 4,
226-230 (2000)
DOI: 10.1177/135245850000600403
Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate
Peter Hùgh
Department of Neurology, The Neuroscience Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Anette Oturai
Department of Neurology, The Neuroscience Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Karen Schreiber
Department of Neurology, The Neuroscience Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Morten Blinkenberg
Department of Neurology, The Neuroscience Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Ole Steen Jùrgensen
Laboratory of Neuropsychiatry, Department of Pharmacology, University of Copenhagen and The Neuroscience Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Lars Ryder
Department of Clinical Immunology, The Center for Laboratory Medicine and Pathology, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Olaf B Paulson
Department of Clinical Immunology, The Center for Laboratory Medicine and Pathology, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Per Soelberg Sùrensen
Department of Clinical Immunology, The Center for Laboratory Medicine and Pathology, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Gitte Moos Knudsen
Department of Clinical Immunology, The Center for Laboratory Medicine and Pathology, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
The purpose of this study was to investigate the relation between APOE genotype and Multiple Sclerosis (MS) in a genetically homogeneous population. We examined 240 patients consulting the MS-clinic during a period of 3 years (1996-1999). The mean age of the patients was 41.7 years (range 19-80 Y, SD 10.0 Y). As a measure of the progression rate (PR) the last registered Expanded Disability Status Scale (EDSS) score was divided by the time span (years) from disease onset until the latest assessment. The APOE genotype was determined from saliva and/or blood samples using PCR-techniques. The prevalence of different APOE genotypes was compared with the allele-distribution in a population of 361 persons from a Danish cross-sectional population study. The frequency of APOE-e4/e4 homozygotes was significantly higher in the MS-group as compared to controls (P<0.05, odds ratio: 2.3), whereas the frequency distribution of other genotypes did not differ significantly. The rate of progression was significantly faster in the APOE-e4/e4 homozygotes compared to other genotypes in the MS group (P<0.05). This study suggests that the APOE-e4/e4 homozygotes have an increased risk of developing MS. MS patients with the APOE-e4/e4 allele may also have an increased rate of disease progression.
Key Words: multiple sclerosis • apolipoprotein E • progression rate • susceptibility • clinical course
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B A Parmenter, D R Denney, S G Lynch, L S Middleton, and L M Harlan
Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms
Multiple Sclerosis,
January 1, 2007;
13(1):
25 - 32.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al.
APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers
Neurology,
May 9, 2006;
66(9):
1373 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M J Sedano, P Calmarza, L Perez, and J M Trejo
No association of apolipoprotein E {epsilon}4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis
Multiple Sclerosis,
February 1, 2006;
12(1):
13 - 18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Pinholt, J L Frederiksen, P S Andersen, and M Christiansen
Apo E in multiple sclerosis and optic neuritis: the Apo E-o4 allele is associated with progression of multiple sclerosis
Multiple Sclerosis,
October 1, 2005;
11(5):
511 - 515.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al.
Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
Arch Neurol,
September 1, 2005;
62(9):
1345 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J N. Zwemmer, T van Veen, L van Winsen, G J van Kamp, F Barkhof, C H Polman, and B M. Uitdehaag
No major association of A poE genotype with disease characteristics and MRI findings in multiple sclerosis
Multiple Sclerosis,
June 1, 2004;
10(3):
272 - 277.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Santos, M. do Carmo Costa, M. E. Rio, M. J. Sa, M. Monteiro, A. Valenca, A. Sa, J. Dinis, J. Figueiredo, L. B. de Almeida, et al.
Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin
Multiple Sclerosis,
April 1, 2004;
10(2):
153 - 157.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. De Stefano, M. L. Bartolozzi, B. Nacmias, V. Zipoli, M. Mortilla, L. Guidi, G. Siracusa, S. Sorbi, A. Federico, and M. P. Amato
Influence of Apolipoprotein E {epsilon}4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis
Arch Neurol,
April 1, 2004;
61(4):
536 - 540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Niino, S Kikuchi, T Fukazawa, I Yabe, and K Tashiro
Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis
Multiple Sclerosis,
August 1, 2003;
9(4):
382 - 386.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Enzinger, S. Ropele, S. Strasser-Fuchs, P. Kapeller, H. Schmidt, B. Poltrum, R. Schmidt, H.-P. Hartung, and F. Fazekas
Lower Levels of N-Acetylaspartate in Multiple Sclerosis Patients With the Apolipoprotein E {epsilon}4 Allele
Arch Neurol,
January 1, 2003;
60(1):
65 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Schreiber, A B Oturai, L P Ryder, H O Madsen, O S Jorgensen, A Svejgaard, and P S Sorensen
Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E)
Multiple Sclerosis,
August 1, 2002;
8(4):
295 - 298.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T Masterman, Z Zhang, D Hellgren, H Salter, M Anvret, L Lilius, L Lannfelt, and J Hillert
APOE genotypes and disease severity in multiple sclerosis
Multiple Sclerosis,
April 1, 2002;
8(2):
98 - 103.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. A. DeSousa, R. H. Albert, and B. Kalman
Cognitive impairments in multiple sclerosis: A review
American Journal of Alzheimer's Disease and Other Dementias,
January 1, 2002;
17(1):
23 - 29.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Chapman, A. D. Korczyn, D. M. Karussis, and D. M. Michaelson
The effects of APOE genotype on age at onset and progression of neurodegenerative diseases
Neurology,
October 23, 2001;
57(8):
1482 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Fazekas, S. Strasser-Fuchs, H. Kollegger, T. Berger, W. Kristoferitsch, H. Schmidt, C. Enzinger, M. Schiefermeier, C. Schwarz, B. Kornek, et al.
Apolipoprotein E {epsilon}4 is associated with rapid progression of multiple sclerosis
Neurology,
September 11, 2001;
57(5):
853 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
